Jane Street’s Theriva Biologics TOVX Stock Holding History

Jane Street’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83K	Buy	331,922 +154,888	+87%	+$45.9K	﹤0.01%	10701
2026 Q1	$34.7K	Buy	+177,034	New	+$34.9K	﹤0.01%	11078
2025 Q4	–	Sell	-36,771	Closed	-$14.9K	–	12393
2025 Q3	$14.9K	Buy	+36,771	New	+$15.9K	﹤0.01%	10561
2024 Q1	–	Sell	-1,902	Closed	-$20.5K	–	10084
2023 Q4	$20.5K	Buy	1,902 +1,209	+174%	+$14.9K	﹤0.01%	8907
2023 Q3	$9.35K	Buy	+693	New	+$10.5K	﹤0.01%	8392
2022 Q2	–	Sell	-1,127	Closed	-$80K	–	10891
2022 Q1	$80K	Buy	+1,127	New	+$76.8K	﹤0.01%	9539
2018 Q4	–	Sell	-75	Closed	-$49K	–	5719
2018 Q3	$49K	Buy	+75	New	+$82.9K	﹤0.01%	4927
2016 Q1	–	Sell	-3	Closed	-$64K	–	4643
2015 Q4	$64K	Buy	+3	New	+$63.5K	﹤0.01%	3848
2015 Q3	–	Sell	-3	Closed	-$70K	–	4147
2015 Q2	$70K	Buy	+3	New	+$60.2K	﹤0.01%	3490

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Jane Street's TOVX Position: Q2 2026 in Review

Jane Street increased its Theriva Biologics (TOVX) stake by 87% in Q2 2026, buying an estimated $45.9K and bringing the position to 331,922 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #10701.

Jane Street first reported a position in TOVX in Q2 2015 and has held it in 9 quarters since. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

Jane Street held 331,922 shares of Theriva Biologics worth $83K as of Q2 2026.
Jane Street bought 154,888 Theriva Biologics shares in Q2 2026, an estimated $45.9K.
Theriva Biologics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10701 holding.
Jane Street first reported a position in Theriva Biologics in Q2 2015 and has held it in 9 quarters since.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.